Stephens Andrew N, Hobbs Simon J, Kang Sung-Woog, Oehler Martin K, Jobling Tom W, Allman Richard
Cleo Diagnostics Ltd., Melbourne 3000, Australia.
Hudson Institute of Medical Research, Clayton 3168, Australia.
Cancers (Basel). 2024 May 28;16(11):2048. doi: 10.3390/cancers16112048.
Pre-surgical clinical assessment of an adnexal mass typically relies on transvaginal ultrasound for comprehensive morphological assessment, with further support provided by biomarker measurements and clinical evaluation. Whilst effective for masses that are obviously benign or malignant, a large proportion of masses remain sonographically indeterminate at surgical referral. As a consequence, post-surgical diagnoses of benign disease can outnumber malignancies up to 9-fold, while less than 50% of cancer cases receive a primary referral to a gynecological oncology specialist. We recently described a blood biomarker signature (multi-marker panel-MMP) that differentiated patients with benign from malignant ovarian disease with high accuracy. In this study, we have examined the use of the MMP, both individually and in combination with transvaginal ultrasound, as an alternative tool to CA-125 for enhanced decision making in the pre-surgical referral process.
附件包块的术前临床评估通常依靠经阴道超声进行全面的形态学评估，并通过生物标志物测量和临床评估提供进一步支持。虽然对于明显良性或恶性的包块有效，但很大一部分包块在手术转诊时超声检查仍无法确定。因此，术后良性疾病的诊断数量可能比恶性疾病多9倍，而不到50%的癌症病例会被首次转诊至妇科肿瘤专科医生处。我们最近描述了一种血液生物标志物特征（多标志物组合-MMP），它能高精度地区分良性和恶性卵巢疾病患者。在本研究中，我们研究了单独使用MMP以及将其与经阴道超声联合使用，作为CA-125的替代工具，以在术前转诊过程中加强决策制定。
